Lates News

Every AI Express, Great Wall Guorui Securities issued a research report on December 12th, giving Ganli Pharmaceutical (603087.SH) a "buy" rating. The main reasons for the rating include: 1) Insulin industry leader, innovative empowerment for growth; 2) Won two bids in centralized procurement, performance rebounded from the bottom; 3) Renewed contracts for centralized procurement, company's insulin business volume and price rise together; 4) Bofan Gelu peptide injection aims to be the world's first biweekly formulation. (Daily Economic News)